FDA机构批准了诺华制药的该种药物,用于治疗其他ITP药物无效或脾切除手术预后不好的1岁以上儿童。Promacta最早于2008年批准用于成人ITP的治疗。“今天Promacta的获批强调了FDA对于充分开发治疗儿科血液学和肿瘤学领域治疗的承诺。
P. Raheja, et al. Thrombopoietin receptor agonists in older patients with primary immune thrombocytopenia : effective and safe?
SaritKalfon等人在2018年《儿科血液肿瘤学杂志》发表了题目为《Cutaneous Hemorrhage Types as Supportive Factors for Predicting Chronic Immune Thrombocytopenia in Chil